Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
- Conditions
- Long Term Follow-up
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT06277037
- Locations
- 🇺🇸
Research and Education Inc., San Diego, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Infectious Disease Care, Hillsborough, New Jersey, United States
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbutus Biopharma Corporation
- Registration Number
- NCT06245291
- Locations
- 🇨🇳
China Medical University Hospital, Taichung City, Taiwan
🇹ðŸ‡The Hiv Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
🇨🇳Chia-yi Christian Hospital, Chia-Yi City, Taiwan
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 164
- Registration Number
- NCT05960240
- Locations
- ðŸ‡ðŸ‡°
Prince of Wales Hospital - Hong Kong, Hong Kong, Hong Kong
🇲🇩Clinial Republican Hospital "Timofei Mosneaga", Chișinău, Moldova, Republic of
🇺🇦Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council, Kyiv, Ukraine
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: Peg-IFNα-2a
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT04980482
- Locations
- 🇺🇸
Arizona Liver Health, Tucson, Arizona, United States
🇺🇸Research and Education, Inc., San Diego, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
- Conditions
- Chronic Hepatitis
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT04775797
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Toronto Liver Center, Toronto, Ontario, Canada
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: ARB-001467Other: Placebo
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02631096
- Locations
- 🇦🇺
Monash Health, Gastroenterology and Hepatology, Clayton, Victoria, Australia
🇳🇿Auckland Clinical Studies Ltd, Auckland, New Zealand
🇦🇺The Alfred, Gastroenterology and Hepatology, Melbourne, Victoria, Australia
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell Carcinoma, Adult
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT02191878
- Locations
- 🇨🇳
Taipei Medical University Hospital, Shuang-Ho Hospital, Taipei, Taiwan
🇰🇷Severence Hospital, Yonsei, University Health System, Seoul, Korea, Republic of
🇺🇸University of California San Francisco, San Francisco, California, United States
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
- Conditions
- Ebola Virus Infection
- Interventions
- Drug: PlaceboDrug: TKM-100802 for Injection
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT02041715
- Locations
- 🇺🇸
Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT01518881
- Locations
- 🇺🇸
Cetero Research, Fargo, North Dakota, United States
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
- Conditions
- CancerAdrenocortical CarcinomaACCNeuroendocrine TumorsNET
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT01262235
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Westchase Oncology Center, Houston, Texas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States